<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Cardiac cachexia: hic et nunc</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Goran</forename><surname>Loncar</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Clinical Hospital Zvezdara</orgName>
								<address>
									<settlement>Belgrade</settlement>
									<country key="RS">Serbia</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution">University of Belgrade</orgName>
								<address>
									<settlement>Belgrade</settlement>
									<country key="RS">Serbia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jochen</forename><surname>Springer</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Innovative Clinical Trials</orgName>
								<orgName type="department" key="dep2">Department of Cardiology and Pneumology</orgName>
								<orgName type="institution">University Medical Center Göttingen (UMG)</orgName>
								<address>
									<settlement>Göttingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Markus</forename><surname>Anker</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">Charité -Universitätsmedizin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Wolfram</forename><surname>Doehner</surname></persName>
							<affiliation key="aff4">
								<orgName type="department">Center for Stroke Research Berlin</orgName>
								<orgName type="institution">Charité Universitätsmedizin</orgName>
								<address>
									<settlement>Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Mitja</forename><surname>Lainscak</surname></persName>
							<email>mitja.lainscak@guest.arnes.si</email>
							<affiliation key="aff5">
								<orgName type="department">Department of Cardiology and Department of Research and Education</orgName>
								<orgName type="institution">General Hospital Celje</orgName>
								<address>
									<settlement>Celje</settlement>
									<country key="SI">Slovenia</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">University of Ljubljana</orgName>
								<address>
									<settlement>Ljubljana</settlement>
									<country key="SI">Slovenia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Department of Cardiology</orgName>
								<orgName type="institution">General Hospital Celje</orgName>
								<address>
									<addrLine>Oblakova 5</addrLine>
									<postCode>SI-3000</postCode>
									<settlement>Celje</settlement>
									<country key="SI">Slovenia</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Cardiac cachexia: hic et nunc</title>
					</analytic>
					<monogr>
						<imprint>
							<date/>
						</imprint>
					</monogr>
					<idno type="MD5">66CACBBCDD6D807B21C31839EDB57D5F</idno>
					<idno type="DOI">10.1002/jcsm.12118</idno>
					<note type="submission">Received: 21 January 2016; Accepted: 18 March 2016</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:19+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Cachexia</term>
					<term>Heart failure</term>
					<term>Prevalence</term>
					<term>Diagnosis</term>
					<term>Treatment</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Cardiac cachexia (CC) is the clinical entity at the end of the chronic natural course of heart failure (HF).</s><s>Despite the efforts, even the most recent definition of cardiac cachexia has been challenged, more precisely, the addition of new criteria on top of obligatory weight loss.</s><s>The pathophysiology of CC is complex and multifactorial.</s><s>A better understanding of pathophysiological pathways in body wasting will contribute to establish potentially novel treatment strategies.</s><s>The complex biochemical network related with CC and HF pathophysiology underlines that a single biomarker cannot reflect all of the features of the disease.</s><s>Biomarkers that could pick up the changes in body composition before they convey into clinical manifestations of CC would be of great importance.</s><s>The development of preventive and therapeutic strategies against cachexia, sarcopenia, and wasting disorders is perceived as an urgent need by healthcare professionals.</s><s>The treatment of body wasting remains an unresolved challenge to this day.</s><s>As CC is a multifactorial disorder, it is unlikely that any single agent will be completely effective in treating this condition.</s><s>Among all investigated therapeutic strategies, aerobic exercise training in HF patients is the most proved to counteract skeletal muscle wasting and is recommended by treatment guidelines for HF.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Epidemiological aspects of cardiac cachexia</head><p><s>Through the prevalence of chronic disease, lack of specific therapies, or non-implementation of existing and evidencebased management, cachexia evolved to a public health issue. <ref type="bibr" target="#b0">1</ref> Most of the epidemiological figures are based on different cachexia definitions and derived from heterogeneous populations. <ref type="bibr" target="#b1">2</ref></s><s>One would hope this would change with a consensus cachexia definition published in 2008. <ref type="bibr" target="#b2">3</ref></s><s>However, literature speaks for itself as we are still in need of quality and quantity on this topic. <ref type="bibr" target="#b3">4</ref></s><s>For heart failure (HF), as for other chronic diseases, only few studies were published, and they remain heterogenous in cachexia definition.</s><s>The recent study in HF again used the old definition, namely, unintentional non-edematous weight loss of &gt;5% over at least 6 months.</s><s>By applying this definition, cachexia was found in 19/238 (10%) HF patients. <ref type="bibr" target="#b4">5</ref></s><s>In fact, a new definition was tested in a single HF study. <ref type="bibr" target="#b5">6</ref></s><s>In 137 patients, the obligatory criterion of weight loss was met by 42 (31%), but when additional three criteria were requested, significantly fewer patients met the cachexia definition [30 (22%) patients, P = 0.0006].</s><s>Interestingly, no difference in survival was seen between those two patient groups.</s><s>The authors therefore challenged the added value of new cachexia definition, more precisely, the addition of criteria on top of obligatory weight loss.</s></p><p><s>Nonetheless, it needs to be acknowledged that cachexia is representing a major burden for patients and the healthcare system.</s><s>In the 1 year analysis of the USA Nationwide Inpatient Sample, cachexia as a primary or secondary diagnosis was reported for 32 131 (0.41%) of all admissions. <ref type="bibr" target="#b6">7</ref></s><s>Cachexia patients were older, had longer length of stay (6 vs. 3 days), and required an average of $4641 more per hospital stay.</s><s>HF was recorded for 19% of cachexia admissions and was the third most common chronic comorbidity (after malignancy, 34%, and chronic obstructive pulmonary disease, 29%).</s><s>Based on burden in terms of costs and outcome, well-conducted cross-sectional or longitudinal epidemiological studies are urgently needed.</s><s>An important source of information should be the Studies Investigating Comorbidities Aggravating Heart Failure that has included HF patients, diabetics, and healthy controls. <ref type="bibr" target="#b7">8</ref></s><s>After an extensive baseline assessment that allows for cachexia diagnosis, they were seen at regular intervals and followed-up for mortality.</s><s>First reports from this study include muscle wasting aspect, which was frequent and associated with reduced physical performance. <ref type="bibr" target="#b8">9</ref></s><s>Along with cachexia definition, health professionals' attitudes across the chronic disease need to be changed.</s><s>Screening for nutritional aspects, weight loss, and correlates in terms of physical performance and quality of life should be part of routine assessment <ref type="bibr" target="#b9">10</ref> as many of abnormalities may be managed in an easy way.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Advances in pathophysiology of cardiac cachexia</head><p><s>The pathophysiology of cardiac cachexia (CC) is complex and multifactorial including several factors interacting in a complex system with immune, metabolic, and neurohormonal consequences, which induce catabolic and anabolic imbalance. <ref type="bibr" target="#b2">3</ref></s><s>The overall net catabolic dominance in HF provokes systemic tissue wasting. <ref type="bibr" target="#b10">11</ref></s><s>Skeletal muscle loss may be the most clinically relevant aspect, as it determines physical capacity and symptomatic severity of HF.</s><s>2]<ref type="bibr" target="#b12">[13]</ref> The final event in progressive tissue wasting in HF is a life-threatening CC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immune activation</head><p><s>5]<ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref> The rise of these inflammatory mediators seems to be combined with inadequately raised or even decreased levels of antiinflammatory mediators such as interleukin-10 and transforming growth factor beta 1. <ref type="bibr" target="#b17">18</ref> The cause of immune activation is still uncertain. <ref type="bibr" target="#b18">19</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Metabolic abnormalities</head><p><s>Evidence is mounting that the abnormal and imbalanced metabolism represents an intrinsic aspect of HF pathophysiology, with fundamental symptomatic and prognostic implications. <ref type="bibr" target="#b10">11</ref></s><s>The concept of metabolic failure in HF include both impaired myocardial energy utilization and metabolic inefficiency at the systemic level.</s><s>The key points in this concept are global anabolic blunting and insulin resistance and catabolic overactivity. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b20">21</ref></s><s>Anabolic deficiency in HF patients induce loss of skeletal muscle mass and function. <ref type="bibr" target="#b21">22</ref></s><s>Men with HF showed reduced circulating testosterone and dehydroepiandrosterone sulfate, and its relation with decreased exercise capacity. <ref type="bibr" target="#b22">23,</ref><ref type="bibr" target="#b23">24</ref></s><s>It is well known that anabolic steroids have a significant role in the quantitative and qualitative regulation of muscle fibre content, leading to increases in muscle mass and strength, as well as improvement in physical performance. <ref type="bibr" target="#b24">25</ref></s><s>The major anabolic hormones modulating protein metabolism in skeletal muscle include insulin, growth hormone (GH), and insulin-like growth factor 1 (IGF-1). <ref type="bibr" target="#b15">16</ref></s><s>It has been previously proved that insulin resistance may play an important role in skeletal muscle dysfunction in HF. <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b25">26</ref> Since IGF-1 has been shown to stimulate protein synthesis and to reduce protein degradation, changes in the GH/IGF-1 axis may impact the anabolic/catabolic balance in the wasting syndrome. <ref type="bibr" target="#b26">27</ref></s><s>Patients with HF-related systolic or diastolic dysfunction have significantly lower plasma levels of total IGF-1, but free IGF-1 is significantly higher than in healthy controls.</s><s>9]<ref type="bibr" target="#b29">[30]</ref> Adiponectin, an adipokine with multiple metabolic actions, increases both locally and globally with HF severity and is highest in cachectic patients. <ref type="bibr" target="#b30">31,</ref><ref type="bibr" target="#b31">32</ref></s><s>Our recent findings may indicate a crosssectional metabolic association of increased serum adiponectin with reduced peripheral muscle mass and muscle strength in non-cachectic, non-diabetic, elderly HF patients. <ref type="bibr" target="#b32">33</ref></s><s>Recent reports suggest the role of changes in small and large intestine function in HF in the pathogenesis of wasting. <ref type="bibr" target="#b33">34,</ref><ref type="bibr" target="#b34">35</ref></s><s>Furthermore, in patients with stable HF, the blood flow in the intestinal arteries is reduced and relates to CC. <ref type="bibr" target="#b35">36</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Neurohormonal abnormalities</head><p><s>The hallmark of HF pathophysiology, as a response to impaired cardiac function, is a general neurohormonal activation via stimulation of the sympathetic nervous system, the renin-angiotensin-aldosterone axis, and the natriuretic peptide system. <ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b37">38</ref></s><s>Chronic autonomic sympathetic/ parasympathetic imbalance is a crucial element of HF pathophysiology.</s><s>Both epinephrine and norepinephrine can cause a catabolic metabolic shift, leading to graded increase in resting energy expenditure in HF patients with CC. <ref type="bibr" target="#b36">37,</ref><ref type="bibr" target="#b37">38</ref> Sustained sympathetic stimulation, as is seen in HF, activates the reninangiotensin-aldosterone axis. <ref type="bibr" target="#b38">39</ref></s><s>Studies have shown that Angiotensin II induces muscle wasting through multiple mechanisms: (i) increased oxidative stress via activation of NADPH oxidase; (ii) increased protein breakdown via reduced IGF-1 and increased cytokine signaling such as glucocorticoid and IL-6; (iii) reduced appetite via alteration in orexigenic/anorexigenic neuropeptide expression in the hypothalamus; (iv) impaired energy balance via inhibition of AMPK; and (v) inhibition of satellite cell function and muscle regeneration. <ref type="bibr" target="#b39">40</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Molecular basis of cachexia</head><p><s>2]<ref type="bibr" target="#b42">[43]</ref> Better understanding of molecular mechanisms of cachexia has provided potentially new treatment targets.</s><s>Skeletal muscle wasting is a consequence of protein synthesis and degradation imbalance.</s><s>Recent studies in CC have evaluated the ubiquitinproteasome pathway (UPP) and autophagy/lysosomal proteolytic pathways to better understand the process of muscle atrophy in HF. <ref type="bibr" target="#b42">[43]</ref><ref type="bibr" target="#b43">[44]</ref><ref type="bibr" target="#b44">[45]</ref> The UPP plays a critical role in skeletal muscle wasting.</s><s>Studies from many groups over the past years have indeed identified many components in the UPP that are induced in atrophying skeletal muscle. <ref type="bibr" target="#b45">46</ref></s><s>he UPP plays a crucial role in the breakdown of myofibrillar proteins. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b46">47</ref></s><s>The overactivation of the UPP in the skeletal muscle of HF patients has been attributed to increased oxidative stress. <ref type="bibr" target="#b47">48,</ref><ref type="bibr" target="#b48">49</ref></s><s>Transcription factors activating the proteasome pathway include particularly the forkhead box class O and nuclear factor-κB (NF-κB) that drive increased expression of the E3 ubiquitin ligases muscle RING-finger protein (MuRF-1) and muscle atrophy F-box. <ref type="bibr" target="#b45">46</ref></s><s>Thus, inhibition of forkhead box class O was found to induce hypertrophy by increasing protein synthesis. <ref type="bibr" target="#b49">50</ref></s><s>Additionally, one recent study demonstrated that angiotensin II induces skeletal muscle atrophy in part by increased muscle-enriched E3 ubiquitin-ligase muscle RING-finger (MuRF-1) expression, which may involve protein kinase-D. <ref type="bibr" target="#b50">51</ref></s><s>Along with overactivated UPP, autophagy and lysosomal protein breakdown are also increased. <ref type="bibr" target="#b51">52</ref></s><s>Unlike UPP, which removes short-living cytosolic and nuclear proteins, the autophagylysosome system accounts for degradation of long-living proteins and protein aggregates.</s><s>There is direct evidence that autophagy signaling is increased in a CC rat model. <ref type="bibr" target="#b44">45</ref></s><s>ome other important molecular mechanisms of controlling muscle mass include: PI3K-AKT signalling, NF-κB, SMAD2 and SMAD3 in myostatin-enhanced and activin A-enhanced proteolysis. <ref type="bibr" target="#b42">43</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Myostatin</head><p><s>Myostatin, a member of the transforming growth factor beta superfamily, is an extracellular cytokine dominantly expressed in skeletal muscles, which is known to play the important role in the negative regulation of muscle mass. <ref type="bibr" target="#b52">53,</ref><ref type="bibr" target="#b53">54</ref></s><s>yostatin appears to be a key player in the integrated physiology of muscle, fat, and bone. <ref type="bibr" target="#b54">55</ref></s><s>It is unclear whether myostatin directly affects fat and bone, or indirectly via muscle.</s><s>Myostatin has high affinity to the activin IIB receptor, and it has been shown that administration of soluble activin IIB receptor resulted in an improvement in body and muscle weights in mice. <ref type="bibr" target="#b55">56</ref></s><s>However, myostatin and the muscle atrophy F-box expression remained unaffected by both the HF and age. <ref type="bibr" target="#b56">57</ref></s><s>generative capacity of skeletal muscle Skeletal muscle has a remarkable ability to maintain its homeostasis against injury or wasting by activating a well orchestrated regenerative response to repair damaged myofibers. <ref type="bibr" target="#b57">58</ref></s><s>Injury leads to activation and proliferation of mitotically quiescent mononuclear cells; satellite cells, which form myoblasts, terminally differentiate and fuse to form multinucleated myotubes. <ref type="bibr" target="#b58">59</ref></s><s>Trials in aged muscle clearly indicate that systemic changes in chronic disease states strongly affect satellite cell regenerative capacity.</s><s>Therefore, identifying mechanisms whereby chronic diseases lead to lower satellite cell function would have the therapeutic potential to reverse the reduction in muscle regeneration seen in cachexia conditions.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Emerging biomarkers of cardiac cachexia</head><p><s>1]<ref type="bibr" target="#b61">[62]</ref> Currently, wasting assessment is limited only to quantification of muscle mass based on imaging and functional tests to quantify muscle function.</s><s>However, all are expensive and only available at medical centers equipped to do so.</s><s>In addition, such tests only allow for wasting detection, but not for patients at risk of developing muscle atrophy. <ref type="bibr" target="#b62">63,</ref><ref type="bibr" target="#b63">64</ref></s><s>hus, the identification of reliable biomarkers that can be used in a cost-effective manner and could guide diagnosis and therapy in routine clinical practice and clinical trials is warranted.</s><s>Several inflammatory, hormonal, and oxidative stress molecules have been suggested as serological markers of prognosis in CC but with doubtful success.</s><s>As individual biomarkers may have limited sensitivity and specificity, multimarker strategies involving mediators of the biological processes modulated by CC may importantly contribute for the diagnosis and management of the disease, as well as for the establishment of new therapeutic targets. <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b59">60,</ref><ref type="bibr" target="#b61">62</ref></s><s>After a brief reminder on biomarkers, which were evaluated in the past (biomarkers of immune activation, metabolic biomarkers, and neurohormonal biomarkers), we will focus in this review on the analysis of the emerging biomarkers for CC/cachexia/sarcopenia proposed recently (Table <ref type="table" target="#tab_0">1</ref>), briefly highlighting the biological processes to which they are related.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Biomarkers of immune activation</head><p><s>Several markers of immune activation have been investigated in the syndrome of cachexia such as TNF-α, soluble tumour necrosis factor receptors (sTNFRs), interleukin 1 beta, interferon γ, and interleukin 6. <ref type="bibr" target="#b15">16,</ref><ref type="bibr" target="#b59">60,</ref><ref type="bibr" target="#b64">65</ref> CC is related to increased circulating levels of TNF-α <ref type="bibr" target="#b65">66,</ref><ref type="bibr" target="#b66">67</ref> , which are involved in the activation of catabolic pathways, in particular of NF-κβ signaling that up-regulates the transcription of members of the proteolytic UPP. <ref type="bibr" target="#b15">16</ref></s><s>tabolic biomarkers Among multiple metabolic disturbances already evaluated in the previous section of this review, this paragraph will focus on adipokines known to be of high importance for regulation of body weight in CC.</s><s>Plasma levels of the adipokines, adiponectin, and leptin may have a role in the detection of muscle, fat, and bone wasting processes. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b31">32</ref></s><s>Adiponectin may play a role in the pathogenesis of body wasting among HF patients. <ref type="bibr" target="#b12">13,</ref><ref type="bibr" target="#b32">33,</ref><ref type="bibr" target="#b67">68</ref></s><s>The catabolic effects of leptin include inhibition of insulin signaling and enhanced lipid oxidation, thus inhibiting anabolic pathways and reducing energy storage. <ref type="bibr" target="#b68">69</ref></s><s>hese effects may have catabolic effects promoting the development of CC in HF patients. <ref type="bibr" target="#b69">70</ref></s><s>Interestingly, leptin levels decrease in CC, but remain higher than in healthy individuals. <ref type="bibr" target="#b70">71</ref></s><s>his decrease in leptin concentrations may be due to the reduction of fat tissue in these patients. <ref type="bibr" target="#b69">70,</ref><ref type="bibr" target="#b70">71</ref></s><s>urohormonal biomarkers Both norepinephrine and epinephrine, as mediators of activated sympathetic nervous system, cause a metabolic shift towards catabolism, leading to a graded increase in resting energy expenditure in patients with CC. <ref type="bibr" target="#b15">16</ref> Ang II-induced body wasting is due to both anorexigenic and catabolic effects. <ref type="bibr" target="#b72">72,</ref><ref type="bibr" target="#b73">73</ref></s><s>Recently, Cichello et al. <ref type="bibr" target="#b74">74</ref> showed a direct effect of Ang II infusion on appetite impairment and body weight loss mostly due to adipose tissue wasting.</s><s>Sanders et al. <ref type="bibr" target="#b75">75</ref> have reported a direct catabolic effect on skeletal muscle by Ang II with increased intracellular protein degradation in murine myotubes through an increased expression of the UPP.</s><s>Increased plasma levels of atrial natriuretic peptide and brain natriuretic peptide were found in cachectic HF patients when compared with non-cachectic patients and healthy volunteers. <ref type="bibr" target="#b59">60,</ref><ref type="bibr" target="#b65">66</ref></s><s>The role of the heart in metabolism is highlighted by the lipolytic activity of natriuretic peptides, as well as by its actions on slowing gastric emptying and absorption. <ref type="bibr" target="#b76">76,</ref><ref type="bibr" target="#b77">77</ref></s><s>The inverse correlation reported between natriuretic peptides and body weight index seems to be explained by the increased energy utilization and thermogenesis induced by these peptides. <ref type="bibr" target="#b78">78</ref></s><s>Plasma cortisol levels are increased in CC patients. <ref type="bibr" target="#b59">60,</ref><ref type="bibr" target="#b66">67,</ref><ref type="bibr" target="#b79">79</ref></s><s>Cortisol is known to induce muscle atrophy by decreasing protein synthesis and increasing proteolysis by four distinct mechanisms.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Novel biomarkers for cardiac cachexia/cachexia</head><p><s>Ghrelin Ghrelin is a 28-amino acid peptide hormone monal tissues. <ref type="bibr" target="#b80">80</ref></s><s>t stimulates the release of growth hormone from the pituitary gland and stimulates food intake. <ref type="bibr" target="#b80">80,</ref><ref type="bibr" target="#b81">81</ref></s><s>Ghrelin is a strong adipogenic and orexigenic molecule, inducing weight gain and adiposity. <ref type="bibr" target="#b82">82</ref></s><s>Ghrelin not only suppresses the production of the pro-inflammatory cytokines tumour necrosis factor, interleukin-1β, and interleukin-6, but also stimulates the anti-inflammatory cytokine interleukin-10. <ref type="bibr" target="#b59">60</ref></s><s>In general, the metabolic changes induced by ghrelin lead to an increase not only in body weight and body fat mass, but also in lean tissue mass, the latter possibly mediated by a reduction in myostatin plasma levels. <ref type="bibr" target="#b60">61</ref></s><s>The resistance of HF patients to the effects of appetite-stimulating peptide ghrelin may be one of the contributing factors in the development of CC. <ref type="bibr" target="#b83">83</ref> Patients with HF and CC have higher plasma ghrelin levels than in those without CC and healthy subjects, which may suggest a compensatory mechanism under the conditions of anabolic/catabolic imbalance, countering further energy deficit and defending against starvation. <ref type="bibr" target="#b84">84</ref></s><s>-terminal agrin fragment (CAF): CAF, derived from the peptide agrin, is a synaptically located key player during the initial formation and maintenance of neuromuscular junctions.</s><s><ref type="bibr" target="#b45">46</ref> In humans, serum CAF levels have recently been shown to be inversely related to appendicular lean mass in men where lower appendicular lean mass was associated with higher CAF.</s><s><ref type="bibr" target="#b85">85</ref> In addition, serum CAF concentrations have been shown to be increased in older adults with sarcopenia compared with aged-matched controls.</s><s><ref type="bibr" target="#b86">86</ref> Resistance exercise training significantly improves muscle strength and quality in older adults and results in an increase of CAF in older adults.</s><s><ref type="bibr" target="#b87">87</ref> It has been proposed as a novel diagnostic marker for muscle wasting in HF patients, which may be useful in identifying patients with CC. <ref type="bibr" target="#b41">42</ref> Growth differentiation factor 15 (GDF-15): Several studies have shown that GDF-15 plays an important role in the pathways of muscle wasting and cachexia.</s><s><ref type="bibr" target="#b45">46,</ref><ref type="bibr" target="#b88">88</ref> Recent findings suggest that GDF-15 induces weight, fat, and muscle wasting, as well as that it decreases activity in mice and may be a promising target for therapeutic interventions in the field of cachexia.</s><s><ref type="bibr" target="#b88">88</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>IC6 and C6M</head><p><s>One recent study showed that type VI collagen turnoverrelated peptides (IC6 and C6M) represent novel biomarkers of muscle mass or change in muscle mass in young men. <ref type="bibr" target="#b89">89</ref></s><s>ype VI collagen is a basement membrane protein expressed in most tissues, but highly abundant in muscle sarcolemma. <ref type="bibr" target="#b90">90</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>P3NP</head><p><s>This collagen fragment N-terminal propeptide of type III procollagen (P3NP) is a measure of skeletal muscle status and a biomarker candidate for muscle anabolism. <ref type="bibr" target="#b87">87</ref></s><s>It is released into circulation during collagen synthesis in soft lean tissue, and its levels have been associated with changes in the lean mass of elderly patients. <ref type="bibr" target="#b62">63,</ref><ref type="bibr" target="#b91">91</ref></s><s>ostatin Although it seems a natural candidate for an atrophy biomarker, as it directly mediates catabolic signaling, the data of a recent study in CC could not confirm the role of circulating myostatin as a biomarker for muscle wasting in humans. <ref type="bibr" target="#b11">12,</ref><ref type="bibr" target="#b62">63,</ref><ref type="bibr" target="#b92">92</ref></s><s>omarkers of muscle mass Serum creatinine levels are understood to be an unspecific marker of muscle wasting. <ref type="bibr" target="#b93">93</ref></s><s>Most studies show that serum creatinine correlate well with measures of skeletal muscle mass. <ref type="bibr" target="#b93">93,</ref><ref type="bibr" target="#b94">94</ref></s><s>Low urine creatinine excretion, as an indirect measure of low muscle mass, is associated with major adverse cardiac events and all-cause mortality in the general population. <ref type="bibr" target="#b95">95</ref></s><s>Plasma gelsolin is an actin-binding protein mainly produced and secreted by myocytes. <ref type="bibr" target="#b96">96</ref></s><s>Recent data demonstrated the prognostic ability of low plasma gelsolin concentrations in hemodialysis patients suggesting that its levels incorporate the degree of systemic inflammation and muscle wasting. <ref type="bibr" target="#b96">96,</ref><ref type="bibr" target="#b97">97</ref></s><s>Plasma gelsolin has been suggested as a marker of muscle mass in haemodialysis patients. <ref type="bibr" target="#b93">93,</ref><ref type="bibr" target="#b98">98</ref></s><s>erapeutic strategies for cardiac cachexia</s></p><p><s>The development of preventive and therapeutic strategies against cachexia, sarcopenia, and wasting disorders is perceived as an urgent need by healthcare professionals. <ref type="bibr" target="#b99">99,</ref><ref type="bibr" target="#b100">100</ref></s><s>owever, the treatment of skeletal muscle wasting remains an unresolved challenge to this day.</s><s>As CC is a multifactorial disorder, it is unlikely that any single agent will be completely effective in treating this condition; thus, it will be necessary to target different pathways.</s><s>Figure <ref type="figure">1</ref> summarizes some potential therapeutic strategies in the management of CC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Preventive strategies for body wasting and cardiac cachexia</head><p><s>Heart failure (HF) management improved over the last decades, and key pharmacological agents are now prescribed to most patients. <ref type="bibr" target="#b101">101</ref></s><s>We, however, keep under treating our patients, particularly with beta blockers but also with ACE inhibitors.</s><s>When considering the landmark report of ACE inhibitor associated prevention of weight loss, <ref type="bibr" target="#b102">102</ref> the adequate daily dose should be pursued.</s><s>For beta blockers, the disproportion is even greater as less than 20% of patients receive target daily dose. <ref type="bibr" target="#b101">101</ref></s><s>As weight gain is the class effect of beta blockers, it is not surprising that in HF, carvedilol was associated with prevention of 6% weight loss (risk reduction vs placebo: 33%) and with &gt;5% weight gain (37% vs. placebo).</s><s>Recently, some ACE inhibitors and beta blockers have been tested for the potential of muscle mass gain.</s><s>Imidapril, a highly lypophylic ACE inhibitor, was tested in a mice tumour model.</s><s>At a daily dose of 10 mg/kg body weight, it attenuated the weight loss. <ref type="bibr" target="#b75">75</ref></s><s>Similar effects were observed in another experiment performed in the murine cancer cachexia model, where imidapril attenuated the muscle and adipose tissue depletion. <ref type="bibr" target="#b103">103</ref></s><s>Transfer to patients with cancer cachexia was already conducted in a randomized placebo controlled trial, but the findings were not published yet. <ref type="bibr" target="#b104">104</ref></s><s>Another attractive concept for prevention of body wasting is the exercise training that is expanding over a variety of chronic disease, including the cachexia patients. <ref type="bibr" target="#b105">105</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Exercise training</head><p><s>Being a part of daily living, exercise is the easiest way to preserve and increase muscle mass; also, it is the most effective anabolic agent with many ancillary effects delivered at no or low costs.</s><s>Data are now emerging for patients with chronic kidney disease <ref type="bibr" target="#b106">[106]</ref><ref type="bibr" target="#b107">[107]</ref><ref type="bibr" target="#b108">[108]</ref> and cancer, <ref type="bibr" target="#b109">109</ref> while there are already existing guidelines for HF <ref type="bibr" target="#b110">110</ref> and chronic obstructive pulmonary disease. <ref type="bibr" target="#b111">111</ref></s><s>The current gold standard against muscle wasting is exercise training. <ref type="bibr" target="#b112">112</ref></s><s>Among all investigated therapeutic strategies, aerobic exercise training (AET) in HF patients is the most proved to counteract skeletal muscle wasting and is recommended by treatment guidelines for HF. <ref type="bibr" target="#b57">58,</ref><ref type="bibr" target="#b113">113</ref></s><s>However, in the paper of Moreira et al., the benefits of AET on skeletal muscle mass, metabolic capacity, and proteasome activity changes were remarkably similar between protocols. <ref type="bibr" target="#b114">114</ref></s><s>Thus, future efforts are warranted to evaluate the AET protocols (e.g.</s><s>durations, types, different intensities) in order to optimize the effects of AET on CC.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Nutritional interventions</head><p><s>The influence of nutrition on protein kinetics in patients with cachexia is poorly understood. <ref type="bibr" target="#b45">46</ref></s><s>Nutritional therapy alone has no effect on the underlying catabolic process of cachexia, but it would be interesting to know the potential synergistic effect from nutritional therapy in conjunction with different drugs.</s><s>There is increasing evidence that protein supplementation acts to increase muscle synthesis and that this effect is increased in conjunction with exercise. <ref type="bibr" target="#b115">115</ref></s><s>he international study group to review dietary protein needs with aging (The PROTAGE study group) has supported the need for 1-1.5 g/kg of high-quality protein to restore muscle in persons with sarcopenia.</s><s><ref type="bibr" target="#b116">116</ref> Additionally, caloric supplementation in HF patients enhanced weight and improved quality of life.</s><s><ref type="bibr" target="#b117">117</ref> Skeletal and cardiac muscle creatine content is reduced in HF, largely because of reduced expression of the creatine-sodium co-transporter.</s><s><ref type="bibr" target="#b10">11</ref> Although there is some evidence of improved skeletal muscle function and exercise duration with chronic oral carnitine administration, there is no evidence of improved cardiac function.</s><s><ref type="bibr" target="#b118">118</ref> Some nutritional interventions such as eicosapentaenoic acid, β-Hydroxy-β-methylbutyrate, and resveratrol may counteract body wasting and muscle loss in animal models, without proved effects in humans.</s><s><ref type="bibr" target="#b119">119</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Figure 1 Therapeutic strategies in the management of cardiac cachexia</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Rehabilitation nutrition</head><p><s>The concept of rehabilitation nutrition as a combination of both rehabilitation and nutrition care management may improve muscle mass and physical performance in disabled elderly. <ref type="bibr" target="#b120">120</ref></s><s>One recent study in HF patients showed that the combination of branched chain amino acid (BCAA) supplementation and resistance exercise can manage sarcopenia and cachexia. <ref type="bibr" target="#b121">121</ref></s><s>The authors found that clinical and physical improvements were caused by the resistance exercise independently from branched chain amino acid supplementation.</s><s>In general, there is consensus that sarcopenia requires appropriate physical therapy and nutrition management in addition to treatment for primary disease. <ref type="bibr" target="#b120">120</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Drugs for cardiac cachexia</head><p><s>Clinical trials with drugs in the field of cachexia remain small, and most are performed in oncology patients. <ref type="bibr" target="#b60">61</ref></s><s>Investigations of drugs that counteract body wasting in HF patients are scarce.</s><s>About 19 drugs that can regulate muscle mass have been reported in the literature so far. <ref type="bibr" target="#b119">119</ref></s><s>These therapeutic interventions include use of anti-inflammatory substances and appetite stimulants.</s><s>Except megestrol, no other drug has yet been recommended by the FDA to prevent or treat muscle atrophy.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Anti-inflammatory drugs</head><p><s>Anti-TNF-α treatment Use of antibodies against pro-inflammatory cytokines could be beneficial in regulating loss of skeletal muscle.</s><s>There are many studies that have highlighted the beneficial effect of some of these antibodies such as anti-TNF α, anti-IL-1, and anti-IL-6 on preserving the muscle loss and restoring their function. <ref type="bibr" target="#b119">119</ref></s><s>Some of these antibodies are under phase I/II/ III trials predominantly in patients with cancer cachexia.</s><s>One animal study showed that anti-TNFα treatment reduces the skeletal muscle wasting in cardiac cachexia and preserves the body mass <ref type="bibr" target="#b122">122</ref> .</s></p><p><s>Thalidomide has shown its anti-cachectic property in cancer patients by down-regulating the TNFα mRNA expression.</s><s>It also prevents the nuclear translocation of NF-κB along with reduction of serum levels of IL-6 and CRP in the cancercachexia patients. <ref type="bibr" target="#b123">123,</ref><ref type="bibr" target="#b124">124</ref></s><s>entoxifylline is also known as suppressor of TNF production, and this property makes it helpful in prevention of skeletal muscle wasting in cancer, sepsis, trauma, and AIDS models. <ref type="bibr" target="#b125">125,</ref><ref type="bibr" target="#b126">126</ref></s><s>HR/AVR118 is a broad-spectrum peptide-nucleic acid immune-modulator with anti-inflammatory activity that targets both cellular pro-inflammatory chemokine and cytokine synthesis (such as TNF-α and IL-6).</s><s>A phase II trial of this drug on patients with advanced cancer and cachexia achieved stabilization of body weight, body fat, and muscle mass with a significant increase in appetite without showing any adverse effect. <ref type="bibr" target="#b127">127</ref></s><s>Additionally, this drug has also been used for treatment of AIDS cachexia patients. <ref type="bibr" target="#b119">119</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appetite stimulants</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Megestrol acetate</head><p><s>9]<ref type="bibr" target="#b130">[130]</ref> Beginning in 1993, megestrol acetate was approved in the USA and in several European countries for the treatment of the anorexia-cachexia syndrome. <ref type="bibr" target="#b131">131</ref></s><s>]<ref type="bibr" target="#b134">[134]</ref> Cannabinoids are known to stimulate appetite as well. <ref type="bibr" target="#b64">65</ref></s><s>he mechanism by which cannabinoids exert their effects is not elucidated, but it was suggested that they may act via endorphin receptors, by inhibiting prostaglandin synthesis, or may suppress cytokine production and/or secretion. <ref type="bibr" target="#b135">135,</ref><ref type="bibr" target="#b136">136</ref></s><s>hrelin administration has therapeutic appeal for its anabolic activities. <ref type="bibr" target="#b137">137</ref></s><s>Ghrelin agonists such as anamorelin carry potential in the treatment of cachexia as they mimic a natural ligand for the growth hormone secretagogue receptor and thus stimulate food intake and appetite. <ref type="bibr" target="#b20">21</ref></s><s>The single study in humans showed that repeated administration of ghrelin improved left ventricular function, exercise capacity, and muscle wasting in patients with HF. <ref type="bibr" target="#b138">138</ref> In the recent study in patients with lung carcinoma and cachexia, anamorelin significantly increased body weight, improved muscle strength and quality of life, and had an overall favourable safety/tolerability profile. <ref type="bibr" target="#b139">139</ref></s><s>The largest human trial with anamorelin intervention ROMANA 2 phase III trial that included 495 patients with non-small cell lung cancer was recently finished, but results have not been reported so far. <ref type="bibr" target="#b140">140</ref></s><s>nother study have shown that the ghrelin agonist, capromelin, increased lean mass and physical performance over one year in older sarcopenic individuals. <ref type="bibr" target="#b141">141</ref></s><s>her drugs for treatment of cardiac cachexia/non-cardiac cachexia Anabolic steroids including testosterone have been effectively used to treat muscle wasting in HF. <ref type="bibr" target="#b21">22</ref> The problem with the administration of anabolic steroids are adverse events that outweigh their potential benefits.</s><s>Selective androgen receptor modulators (SARMs) belong to a relatively new class of therapeutics currently under development that possesses anabolic properties without adverse effects on prostate, skin, or hair frequently associated with testosterone treatment. <ref type="bibr" target="#b55">56,</ref><ref type="bibr" target="#b142">142</ref></s><s>nobosarm, an orally bioavailable non-steroidal SARM with tissue-specific anabolic and androgenic activity, has shown amelioration in lean mass and physical function in healthy younger as well as in healthy elderly men and postmenopausal women. <ref type="bibr" target="#b143">143,</ref><ref type="bibr" target="#b144">144</ref></s><s>In patients with cancer, treatment with enobosarm confirmed its beneficial effect on skeletal muscle mass and physical performance. <ref type="bibr" target="#b145">145</ref></s><s>Dobs et al. established a SARM, enobosarm, as a new drug for the prevention and treatment of muscle wasting in cancer patients. <ref type="bibr" target="#b146">146</ref></s><s>Takagi et al. recently presented another new SARM (TEI-E0001) as a novel long acting SARM. <ref type="bibr" target="#b147">147</ref></s><s>In the animal model, they demonstrated that TEI-E0001 has potent anabolic activity on the muscle and bone, while reducing androgenic side effects.</s><s>GLPG0492(galapagos) is another non-steroidal SARM that has shown its efficacy on muscle by increasing muscle fibre size and skeletal muscle function in the hind limb of immobilized mice and in Duchenne muscular dystrophy patients, respectively. <ref type="bibr" target="#b148">148,</ref><ref type="bibr" target="#b149">149</ref></s><s>2 receptor agonists β-2 receptor agonism is involved in the regulation of skeletal muscle proliferation and differentiation programmes, and these properties make this receptor signaling pathway a novel therapeutic target for controlling the skeletal muscle wasting.</s><s><ref type="bibr" target="#b150">150,</ref><ref type="bibr" target="#b151">151</ref> A novel anabolic agent espindolol (MT-102) has recently been established.</s><s>Animal experiments in 19month-old male Wistar Han rats have shown that espindolol can abolish the effects of ageing-related body and muscle wasting.</s><s><ref type="bibr" target="#b152">152</ref> It appears to possess three potential pharmacological targets in cancer cachexia: (i) reduced catabolism through non-selective β-blockade, (ii) reduced fatigue and thermogenesis through central 5-HT1a antagonism, and (iii) increased anabolism through partial β-2 receptor agonism.</s><s><ref type="bibr" target="#b153">153</ref> The ACT-ONE trial has recently demonstrated that MT-102 counteracted body wasting and some aspects of physical performance in 87 patients with cancer cachexia.</s><s><ref type="bibr" target="#b45">46,</ref><ref type="bibr" target="#b154">154</ref> Another β-2 receptor agonist, formoterol, induced reduction of muscle weight loss in cachectic tumour-bearing rats and showed no influence on heart weight and seems to improve heart function.</s><s><ref type="bibr" target="#b155">155</ref> Thus, MT-102 and formoterol seem to be prospective new drugs to treat patients with cancer cachexia, especially if they present signs of declined cardiac function.</s><s><ref type="bibr" target="#b45">46</ref> Myostatin antagonist REGN1033 and Bimagrumab (BYM338) are two human mono-clonal antibodies against myostatin.</s><s><ref type="bibr" target="#b119">119</ref> The administration of myostatin antagonist (REGN1033) induced increase of muscle mass, force, and physical performance outcomes in aged mice and prevents the loss of muscle mass.</s><s><ref type="bibr" target="#b156">156</ref> The treatment with BYM338 enhances differentiation of primary human skeletal myoblasts and increases skeletal muscle mass in mice by blocking the activin type II B receptors (ActRIIB).</s><s><ref type="bibr" target="#b119">119</ref> A soluble form of the activin type IIB receptor (ActRIIB/Fc; ACVR2B-ACE031) can inhibit myostatin signalling and significantly increases muscle growth in mice bearing cancer.</s><s><ref type="bibr" target="#b157">157</ref> Overall BYM338, REGN1033, and soluble ActRIIB/Fc are promising drugs that have the ability to regulate muscle wasting/cachexia by blocking myostatin/activin signaling under diverse pathological conditions including cancer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Enzyme inhibitors</head><p><s>Several enzyme inhibitors (Cox2 inhibitors, Trichostatin A,PDE inhibitors-torbafylline) showed promising results in suppressing muscle loss in animal models of cachexia. <ref type="bibr" target="#b119">119</ref></s><s>Additionally, Cox2 inhibitor, celecoxib has showed a beneficial effect against muscle loss in patients with cancer and arthritis-induced cachexia.</s></p><p><s>IGF1 analogues 'Long arginine' IGF1 is a modified form of IGF1 that has a long circulation time, binds to more tissue targets and is more potent than endogenous IGF1. <ref type="bibr" target="#b42">43</ref></s><s>Its ability to induce myoblast proliferation offers greater therapeutic potential.</s><s>However, several more potent variants have been developed that have prolonged circulation times and have reduced association with inhibitory IGF1-binding proteins. <ref type="bibr" target="#b158">158</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>APD209</head><p><s>APD209 is an oral, fixed-dose combination of megestrol and formoterol for use in treatment of cancer cachexia at the moment. <ref type="bibr" target="#b119">119</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statins</head><p><s>Along with the primary effect of cholesterol lowering, statins have many ancillary actions that may be relevant for body wasting. <ref type="bibr" target="#b64">65</ref></s><s>In this context, the fear of muscle-related side effects needs to be put into clinical context and assessed appropriately before statins are either withheld or withdrawn in patients with sarcopenia/cachexia. <ref type="bibr" target="#b159">159</ref> In fact, several reports suggest statins may even have beneficial effects by preserving or even increasing body compartments (muscle and fat).</s><s>In an animal model of cancer cachexia, simvastatin vs. placebo attenuated body weight loss (28-48%, depending on dose, P &lt; 0.05 for all), mainly because of the preservation of muscle mass. <ref type="bibr" target="#b160">160</ref></s><s>With the improvement of cardiac function, this translated into improved survival with simvastatin.</s><s>Statins were also associated with an increase of lean mass as measured by DEXA following 12 week resistance training. <ref type="bibr" target="#b161">161</ref></s><s>ean mass gain was higher in those subjects who had higher dietary cholesterol intake and higher serum cholesterol.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Muscle regeneration</head><p><s>One theoretical approach is to use stem cells to help replace degenerated muscle tissue. <ref type="bibr" target="#b92">92</ref></s><s>Recent studies demonstrated different types of stem cells that have been attributed to be endowed with muscle regenerative potential. <ref type="bibr" target="#b58">59,</ref><ref type="bibr" target="#b162">162</ref></s><s>The possibility to reprogram all the cells of the body to muscle presents a revolutionary concept, importantly widening the range of muscle sources for the treatment of muscle dysfunction.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Ventricular assist device</head><p><s>The improvement of cardiovascular circulatory support by ventricular assist device in terminal HF patients corrects GH/IGF-1 signaling along with amelioration of muscle structure and function with enhancement of oxidative muscle metabolism. <ref type="bibr" target="#b163">163</ref></s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Gaps in evidence-based management of body wasting and cachexia</head><p><s>To improve design of interventional trials, we need to gain better insight into epidemiology, trajectories, and pathways of body wasting in chronic disease.</s><s>It is not irrelevant how and why the patients die. <ref type="bibr" target="#b164">164</ref></s><s>Knowing the most common causes and also modes of death can lead to application of well-established therapies, e.g.</s><s>beta blockers or devices for sudden cardiac death.</s><s>Body wasting and cachexia are usually recognized when patients experience certain limitations in activities of daily living; at this stage, underlying mechanisms are well advanced and tissue damage is already present.</s><s>Biomarkers that could pick up the changes before they convey into clinical manifestations would be of great importance.</s><s>For these purposes, blood and/or urine analysis is attractive, with several candidates to assess muscle wasting and quality that are in clinical testing. <ref type="bibr" target="#b87">87,</ref><ref type="bibr" target="#b89">89,</ref><ref type="bibr" target="#b165">165</ref></s><s>The complex biochemical network related with CC and HF pathophysiology underlines that a single biomarker cannot reflect all of the features of the disease.</s><s>Consequently, future studies should be focused on the use of a combination of multiple biomarkers in order to establish an optimal network that better reflects all of the characteristic of the syndrome.</s><s>As there is up-regulation of proteolysis in CC, it is expected an augmentation of cleavage products from proteases as caspases, calpains, or cathepsins. <ref type="bibr" target="#b59">60,</ref><ref type="bibr">166</ref></s><s>Its measurement may more specifically express cachectic biological processes leading to fatal outcome.</s><s>In addition to proteolysis, other protein modifications such as oxidation as a result of oxidative stress, <ref type="bibr" target="#b59">60,</ref><ref type="bibr">166</ref> which also should be considered in the definition of multimarker strategies.</s><s>Finally, whether use of proteomics and metabolomics analysis may contribute in better biomarker evaluation of CC is still unknown as this has not been still assessed in that condition.</s></p><p><s>A better understanding of pathophysiological pathways in body wasting will contribute to establish potentially novel treatment strategies.</s><s>Whether the use of microdyalisis on skeletal muscle may be of help in regard to this aim will be soon evaluated in our study in acutely decompensated HF patients.</s><s>Microdialysis is a technique designed to explore and monitor the chemistry of extracellular fluid of virtually any tissue or cell culture medium. <ref type="bibr" target="#b166">167</ref></s><s>he intriguing concept to reprogram all the cells of the body to muscle presents a revolutionary idea, importantly widening the range of muscle sources for the treatment of muscle dysfunction. <ref type="bibr" target="#b58">59</ref></s><s>Further studies are warranted on the potential of stem cell therapy to counteract the muscle wasting including identification of mechanisms whereby chronic disease lead to lower satellite cell function that would have the therapeutic potential to reverse the reduction in muscle regeneration seen in cachexia conditions.</s></p><p><s>The scientific community is much engaged in interventional trials to find a remedy for muscle wasting and cachexia.</s><s>It should be emphasized that translation of benefits from the non-cachectic population to cachexia may not be straightforward as drug pharmacokinetics changes with body wasting. <ref type="bibr" target="#b167">168,</ref><ref type="bibr" target="#b168">169</ref></s><s>Ongoing trials are heterogenous in design and include a wide span of chronic disease. <ref type="bibr" target="#b94">94,</ref><ref type="bibr" target="#b112">112</ref></s><s>A direct comparison of findings will be difficult as enrolment criteria (including sarcopenia/cachexia definition) vary and because different endpoints are being pursued.</s><s>On top of that, different analysis plans are used for different regulatory authorities.</s><s>Many experts have called for a unified approach, and their notion has now materialized in a consensus document. <ref type="bibr" target="#b169">170</ref></s><s>Following this guidance, better use of available resources for adequately powered trials with meaningful clinical endpoints is anticipated.</s><s>Most of the candidate compounds are newly developed; thus, safety issues deserve particular attention.</s><s>This should not be limited only to acute side effects but also to drug-drug interactions and long-term safety profile.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusions</head><p><s>Cardiac cachexia (CC) is the clinical entity at the end of the chronic natural course of HF.</s><s>A simplistic view could be that with effective prevention, incidence of CC would be low or non-existing.</s><s>In the real world, multiple factors influence disease trajectories in this syndrome.</s><s>Detection of the pathways that modulate muscle wasting and dysfunction will provide important information for the definition of CC-specific biomarkers and for the development of medications that counteract muscle impairment, which will certainly improve the treatment of this serious disorder.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Biomarkers of cardiac and non-cardiac cachexia</s></p></div></figDesc><table><row><cell></cell><cell>Biomarker</cell><cell>Cardiac cachexia</cell><cell>References</cell><cell>Non-cardiac cachexia</cell><cell>References</cell></row><row><cell>Biomarkers of immune activation</cell><cell>TNF-α sTNFRs IL-1 IL-6</cell><cell>↑ ↑ ↑ ↑</cell><cell>16,38,60,65,68 38,42 38,42 38,42,68</cell><cell>↑ ↑ ↑ ↑</cell><cell>171-175 40 171,175 176,177</cell></row><row><cell>Metabolic biomarkers</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Adiponectin Leptin Insulin Testosterone/DHEA Growth hormone IGF-1 Uric acid</cell><cell>↑ ↑ ↑ ↓ ↑ ↓ ↑</cell><cell>31,33,68 28,69-71 11,26,181,182 22-24 79,181,186,187 27,79,181 11,191</cell><cell>↑ ↑ ↑ ↓ ↑ ↓ ↑</cell><cell>178,179 180 183,184 185 188,189 189,190 192</cell></row><row><cell>Neurohormonal biomarkers</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Norepinephrine Epinephrine Angiotensin II Natriuretic peptides Cortisol</cell><cell>↑ ↑ ↑ ↑ ↑</cell><cell>16,37,38 16,37,38 40,72,73 11,60 60,67,79,195</cell><cell>↑ ↑ ↑ ↑ ↑</cell><cell>193 193 74,75 77,194 196</cell></row><row><cell>Emergent biomarkers</cell><cell>Ghrelin CAF GDF15 IC6 and C6M P3NP Myostatin</cell><cell>↑ ----↑↓</cell><cell>61,83,84 ----5,199-204</cell><cell>↑ ↑ ↑ ↑ ↓ *↓ **↑=</cell><cell>80,197,198 85,86 88 89,93 90 * 205 ** 55,206-209</cell></row><row><cell>Markers of muscle mass</cell><cell>Serum creatinine Urinary creatinine</cell><cell>--</cell><cell>--</cell><cell>↓ ↓</cell><cell>93,210,211 95</cell></row><row><cell></cell><cell>Gelsolin</cell><cell>-</cell><cell>-</cell><cell>↓</cell><cell></cell></row></table><note><p><s>96C6M, MMP-generated degradation fragment of collagen 6; CAF, C-terminal agrin fragment; CC, cardiac cachexia; DHEA, Dehydroepiandrosterone; GDF15, growth differentiation factor 15; IC6, type VI collagen N-terminal globular domain epitope; IGF-1, Insulin-like growth factor 1; IL-1, Intereleukin 1; IL-6, Interleukin 6; P3NP, N-terminal propeptide of type III procollagen; sTNFRs, Soluble tumour necrosis factor receptors (sTNFRs); TNF-α, tumour necrosis factor alpha. *Circulating myostatin levels in non-cardiac cachexia; **Local myostatin expression in non-cardiac cachexia.-,</s><s>no trials to date.</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 246-260 DOI: 10.1002/jcsm.12118</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>The authors certify that they comply with the ethical guidelines for authorship and publishing of the Journal of Cachexia, Sarcopenia and Muscle. <ref type="bibr" target="#b211">212</ref></s><s>This paper was also published in parallel in the International Journal of Cardiology.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p><s>None declared.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Cachexia as a major public health problem: frequent, costly, and deadly</title>
		<author>
			<persName><forename type="first">J</forename><surname>Farkas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantar-Zadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="173" to="178" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Cachexia as a major underestimated and unmet medical need: facts and numbers</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="1" to="5" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Cachexia: a new definition</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Argile's</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Baracos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Guttridge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">27</biblScope>
			<biblScope unit="page" from="793" to="799" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Prevalence, incidence and clinical impact of cachexia: facts and numbers-update</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="261" to="263" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Prevalence of cachexia in chronic heart failure and characteristics of body composition and metabolic status</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kistorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zerahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Frystyk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Endocrine</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="626" to="634" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Influence of additional criteria from a definition of cachexia on its prevalence -good or bad thing?</title>
		<author>
			<persName><forename type="first">T</forename><surname>Letilovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vrhovac</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="797" to="801" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">One-year prevalence, comorbidities and cost of cachexiarelated inpatient admissions in the USA</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Arthur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Noone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Van Doren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Roy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Blanchette</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs Context</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">212265</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rosano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jordan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="187" to="194" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Muscle wasting in patients with chronic heart failure: results from the studies investigating co-morbidities aggravating heart failure (SICA-HF)</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fülster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tacke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sandek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Ebner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tschöpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="512" to="519" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Health professionals&apos; attitudes toward detection and management of cancer-related anorexiacachexia syndrome, and a proposal for standardized assessment</title>
		<author>
			<persName><forename type="first">Del</forename><surname>Fabbro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Jatoi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fearon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Di Tomasso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vigano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Community Support Oncol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="181" to="187" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Metabolic impairment in heart failure: the myocardial and systemic perspective</title>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Frenneaux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1388" to="1400" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Metabolism and the heart: an overview of muscle, fat, and bone metabolism in heart failure</title>
		<author>
			<persName><forename type="first">G</forename><surname>Loncar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Fülster</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Popovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">162</biblScope>
			<biblScope unit="page" from="77" to="85" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Relationship between high circulating adiponectin with bone mineral density and bone metabolism in elderly males with chronic heart failure</title>
		<author>
			<persName><forename type="first">B</forename><surname>Bozic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Loncar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prodanovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Radojicic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Cvorovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dimkovic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Card Fail</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="301" to="307" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Elevated circulating levels of tumor necrosis factor in severe chronic heart failure</title>
		<author>
			<persName><forename type="first">B</forename><surname>Levine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kalman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mayer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Fillit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Packer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">323</biblScope>
			<biblScope unit="page" from="236" to="241" />
			<date type="published" when="1990">1990</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Increased concentrations of tumour necrosis factor in &quot;cachectic&quot; patients with severe chronic heart failure</title>
		<author>
			<persName><forename type="first">J</forename><surname>Mcmurray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Abdullah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Dargie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shapiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br Heart J</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="356" to="358" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Recent insights on the molecular mechanisms and therapeutic approaches for cardiac cachexia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Martins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vitorino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Moreira-Gonçalves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Amado</forename><forename type="middle">F</forename><surname>Duarte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Biochem</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="8" to="15" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Schefold</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Heart Fail Clin</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="549" to="560" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy</title>
		<author>
			<persName><forename type="first">P</forename><surname>Aukrust</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ueland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lien</forename><forename type="middle">E</forename><surname>Bendtzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Andreassen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Cardiol</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="376" to="382" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Autonomic imbalance and immune activation in chronic heart failure-pathophysiological links</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Jankowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Piepoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Banasiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Poole-Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Res</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="434" to="445" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Usefulness of minimal modelling to assess impaired insulin sensitivity in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">T</forename><surname>Szabo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Habedank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rauchhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sandek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">147</biblScope>
			<biblScope unit="page" from="47" to="51" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Research on cachexia, sarcopenia and skeletal muscle in cardiology</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Coats</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="219" to="223" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Skeletal myopathy in patients with chronic heart failure: significance of anabolic-androgenic hormones</title>
		<author>
			<persName><forename type="first">K</forename><surname>Josiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Jankowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Piepoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Banasiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="287" to="296" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Reduction in circulating testosterone relates to exercise capacity in men with chronic heart failure</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Jankowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Ponikowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Borodulin-Nadzieja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Banasiak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Card Fail</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="442" to="450" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Jankowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Biel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Majda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Szklarska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lopuszanska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Medras</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="1829" to="1837" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement</title>
		<author>
			<persName><forename type="first">F</forename><surname>Kadi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">154</biblScope>
			<biblScope unit="page" from="522" to="528" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Insulin resistance in heart failure: differences between patients with reduced and preserved left ventricular ejection fraction</title>
		<author>
			<persName><forename type="first">N</forename><surname>Scherbakov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sandek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Szabó</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Töpper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">A</forename><surname>Jankowska</surname></persName>
		</author>
		<idno type="DOI">10.1002/ejhf.317</idno>
		<idno>doi:10.1002/ ejhf.317</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Brink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Anwar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delafontaine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="111" to="121" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Leptin and the clinical cardiovascular risk</title>
		<author>
			<persName><forename type="first">M</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">S</forename><surname>Bedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Arora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Khosla</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="266" to="271" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Adiponectin is increased in cardiac cachexia irrespective of body mass index</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Araujo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lourenco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rocha-Goncalves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Bettencourt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="567" to="572" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Serum adipokine zinc alpha-2 glycoproteinand lipolysis in cachectic and noncachectic heart failure patients: relationship with neurohormonal and inflammatory biomarkers</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tedeschi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Pilotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Parenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Vicini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Coghi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Montanari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metab Clin Exp</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="37" to="42" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">C</forename><surname>Kistorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Faber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galatius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gustafsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Frystyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Flyvbjerg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="1756" to="1762" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Plasma adiponectin in heart failure with and without cachexia: catabolic signal linking catabolism, symptomatic status, and prognosis</title>
		<author>
			<persName><forename type="first">T</forename><surname>Szabó</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Scherbakov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sandek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nutr Metab Cardiovasc Dis</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="50" to="56" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Association of adiponectin with peripheral muscle status in elderly patients with heart failure</title>
		<author>
			<persName><forename type="first">G</forename><surname>Loncar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Bozic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Düngen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Prodanovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Intern Med</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="818" to="823" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">The small intestine: a critical linkage in pathophysiology of cardiac cachexia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sandek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valentova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">146</biblScope>
			<biblScope unit="page" from="277" to="278" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">The small intestine: a critical linkage in pathophysiology of cardiac cachexia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Celik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iyisoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">C</forename><surname>Yuksel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">143</biblScope>
			<biblScope unit="page" from="200" to="201" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Intestinal blood flow in patients with chronic heart failure: a link with bacterial growth, gastrointestinal symptoms, and cachexia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Sandek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Swidsinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Schroedl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Watson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Valentova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Herrmann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="page" from="1092" to="1102" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The syndrome of cardiac cachexia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sharma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">85</biblScope>
			<biblScope unit="page" from="51" to="66" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Cardiac cachexia*a syndrome with impaired survival and immune and neuroendocrine activation</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajs</forename><surname>Coats</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chest J</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="836" to="847" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Neurohormonal modulation in chronic heart failure</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ferrara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mastrorilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Pasanisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Censi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'aiello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fucili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J Suppl</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="D3" to="D11" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Mechanisms of cachexia in chronic disease states</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Delafontaine</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med Sci</title>
		<imprint>
			<biblScope unit="volume">350</biblScope>
			<biblScope unit="page" from="250" to="256" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Cancer cachexia: mediators, signaling, and metabolic pathways</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Fearon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Glass</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Guttridge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell Metab</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="153" to="166" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Molecular mechanisms and treatment targets of muscle wasting and cachexia in heart failure: an overview</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ebner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Elsner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Support Palliat Care</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="15" to="24" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Muscle wasting in disease: molecular mechanisms and promising therapies</title>
		<author>
			<persName><forename type="first">S</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Nathan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Drug Discov</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="58" to="74" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Exercise training prevents oxidative stress and ubiquitin-proteasome system overactivity and reverse skeletal muscle atrophy in heart failure</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Cunha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Bacurau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Paixão</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Campos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Ferreira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">e41701</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Autophagy signaling in skeletal muscle of infarcted rats</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Jannig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Bechara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Bozi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Bacurau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Monteiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e85820</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Highlights from the 7th Cachexia Conference: muscle wasting pathophysiological detection and novel treatment strategies</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ebner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Steinbeck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="27" to="34" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Role of the ubiquitinproteasome pathway in muscle atrophy in cachexia</title>
		<author>
			<persName><forename type="first">D</forename><surname>Attaix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Combaret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Béchet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Taillandier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Support Palliat Care</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="262" to="266" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Oxidative stress, chronic disease, and muscle wasting</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Moylan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Reid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Muscle Nerve</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="411" to="429" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Tisdale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Support Oncol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="209" to="217" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">SIRT1 by blocking the activities of FoxO1 and 3 inhibits muscle atrophy and promotes muscle growth</title>
		<author>
			<persName><forename type="first">D</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Goldberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="page" from="30515" to="30526" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Angiotensin II induces skeletal muscle atrophy by activating TFEB-mediated MuRF1 expression</title>
		<author>
			<persName><forename type="first">Du</forename><surname>Bois</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Pablo</forename><surname>Tortola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lodka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circ Res</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="424" to="436" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Acetylation and deacetylation: novel factors in muscle wasting</title>
		<author>
			<persName><forename type="first">N</forename><surname>Alamdari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Aversa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Castillero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">O</forename><surname>Hasselgren</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">The role of myostatin in muscle wasting: an overview</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Elkina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="143" to="151" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Myostatin-from the mighty mouse to cardiovascular disease and cachexia</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">B</forename><surname>Dschietzig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chim Acta</title>
		<imprint>
			<biblScope unit="volume">433</biblScope>
			<biblScope unit="page" from="216" to="224" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Mechanism and novel therapeutic approaches to wasting in chronic disease</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ebner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantar-Zadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Maturitas</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="199" to="206" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance</title>
		<author>
			<persName><forename type="first">S</forename><surname>Busquets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toledo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Orpi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Massa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Porta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Capdevila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="37" to="43" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Exercise training attenuates MuRF-1 expression in the skeletal muscle of patients with chronic heart failure independent of age: the randomized Leipzig Exercise Intervention in Chronic Heart Failure and Aging catabolism study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gielen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sandri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kozarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kratzsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Teupser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Thiery</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="2716" to="2727" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Sources for skeletal muscle repair: from satellite cells to reprogramming</title>
		<author>
			<persName><forename type="first">D</forename><surname>Sirabella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>De Angelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Berghella</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="125" to="136" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<title level="m" type="main">Skeletal muscle stem cells in the spotlight: the satellite cell</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Yablonka-Reuveni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Day</surname></persName>
		</author>
		<editor>Cohen IS, Gaudette GR</editor>
		<imprint>
			<date type="published" when="2011">2011</date>
			<publisher>Springer</publisher>
			<biblScope unit="page" from="173" to="200" />
			<pubPlace>New York, New York</pubPlace>
		</imprint>
	</monogr>
	<note>Regenerating the heart</note>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Biomarkers for cardiac cachexia: reality or utopia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Martins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Vitorino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Amado</forename><forename type="middle">F</forename><surname>Duarte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chim Acta</title>
		<imprint>
			<biblScope unit="volume">436</biblScope>
			<biblScope unit="page" from="323" to="328" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Treatment of cachexia: an overview of recent developments</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">184</biblScope>
			<biblScope unit="page" from="736" to="742" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Emerging biomarkers in heart failure and cardiac cachexia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Loncar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Omersa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Cvetinovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Arandjelovic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Mol Sci</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="23878" to="23896" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Muscle wasting: an overview of recent developments in basic research</title>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="193" to="198" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Assessing skeletal muscle mass: historical overview and state of the art</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">B</forename><surname>Heymsfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Adamek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="9" to="18" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Cardiac cachexia: a systematic overview</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="227" to="252" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">The relationship between tumor necrosis factor-a, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">A</forename><surname>Vaz Pérez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Zimmermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Volk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="39" to="43" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Clark</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Leyva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rauchhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kemp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="683" to="693" />
			<date type="published" when="1999">1999</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Mcentegart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Awede</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Petrie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sattar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Dunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Macfarlane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur Heart J</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="829" to="835" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Leptin as a new diagnostic tool in chronic heart failure</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Schulze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kratzsch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chim Acta</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Schulze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Kratzsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Schoene</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gielen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="33" to="40" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pflaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rauchhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">F</forename><surname>Godsland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Egerer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cicoira</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">insulin sensitivity and growth hormone binding protein in chronic heart failure with and without cardiac cachexia</title>
		<author>
			<persName><surname>Leptin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Endocrinol</title>
		<imprint>
			<biblScope unit="volume">145</biblScope>
			<biblScope unit="page" from="727" to="735" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Angiotensin II, oxidative stress and skeletal muscle wasting</title>
		<author>
			<persName><forename type="first">S</forename><surname>Sukhanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Semprun-Prieto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Michael</forename><surname>Tabony</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Higashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Galvez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Med Sci</title>
		<imprint>
			<biblScope unit="volume">342</biblScope>
			<biblScope unit="page" from="143" to="147" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Yoshida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Tabony</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Galvez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">E</forename><surname>Mitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Higashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sukhanov</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell Biol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="2322" to="2332" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">1-Sarcosine-angiotensin II infusion effects on food intake, weight loss, energy expenditure, and skeletal muscle UCP3 gene expression in a rat model</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Cichello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Weisinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Schuijers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jois</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="239" to="246" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Angiotensin II directly induces muscle protein catabolism through the ubiquitinproteasome proteolytic pathway and may play a role in cancer cachexia</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Russell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Tisdale</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Cancer</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="425" to="434" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Nutrition, metabolism, and the complex pathophysiology of cachexia in chronic heart failure</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cardiovasc Res</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="298" to="309" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Natriuretic peptides: a new lipolytic pathway in human adipocytes</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sengenès</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Berlan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Glisezinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lafontan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Galitzky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">FASEB J</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1345" to="1351" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Cross-talk between the heart and adipose tissue in cachectic heart failure patients with respect to alterations in body composition: a prospective study</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Christensen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Kistorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Keller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zerahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Frystyk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Metabolism</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="141" to="149" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">P</forename><surname>Chua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Swan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">J</forename><surname>Kox</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="526" to="534" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title/>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Nogueiras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Andermann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">B</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Argente</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Metab</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="437" to="460" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Ghrelin for cachexia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Akamizu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kangawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="169" to="176" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Ghrelin: a gastric peptide that regulates food intake and energy homeostasis</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Yamaguchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kangawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nakazato</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Regul Pept</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="11" to="19" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Hormonal consequences and prognosis of chronic heart failure</title>
		<author>
			<persName><forename type="first">P</forename><surname>Attanasio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Endocrinol Diabetes Obes</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="224" to="230" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Elevated circulating level of ghrelin in cachexia associated with chronic heart failure</title>
		<author>
			<persName><forename type="first">N</forename><surname>Nagaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uematsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kojima</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Date</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nakazato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Okumura</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="page" from="2034" to="2038" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">C-terminal agrin fragment as a potential marker for sarcopenia caused by degeneration of the neuromuscular junction</title>
		<author>
			<persName><forename type="first">M</forename><surname>Drey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Sieber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Uter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dahinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Fariello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Gerontol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="76" to="80" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Elevated levels of a C-terminal agrin fragment identifies a new subset of sarcopenia patients</title>
		<author>
			<persName><forename type="first">S</forename><surname>Hettwer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dahinden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kucsera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Farina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Fariello</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Gerontol</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="69" to="75" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Biomarkers of muscle quality: Nterminal propeptide of type III procollagen and C-terminal agrin fragment responses to resistance exercise training in older adults</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Fragala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">R</forename><surname>Jajtner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Beyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Townsend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">S</forename><surname>Emerson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Scanlon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="139" to="148" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Growth differentiating factor-15 (GDF-15) induces anorexia and cachexia in mice: a novel pathway for cachexia</title>
		<author>
			<persName><forename type="first">L</forename><surname>Lerner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Guillory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Winston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Weiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gyuris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="295" to="343" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Type VI collagen turnover-related peptidesnovel serological biomarkers of muscle mass and anabolic response to loading in young men</title>
		<author>
			<persName><forename type="first">A</forename><surname>Nedergaard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Karsdal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Henriksen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kjaer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Lou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachex Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="267" to="275" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Sabatelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Bönnemann</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neuropathol Exp Neurol</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="144" to="154" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">N-terminal propeptide of type III procollagen as a biomarker of anabolic response to recombinant human GH and testosterone</title>
		<author>
			<persName><forename type="first">S</forename><surname>Bhasin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kawakub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">T</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yarasheski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">J</forename><surname>Opiteck</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="4224" to="4233" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis</title>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">C</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Tomlinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Walding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Isherwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">G</forename><surname>Dougall</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="157" to="169" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Z</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Tayek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Ix</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Noori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Benner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="19" to="29" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Highlights of mechanistic and therapeutic cachexia and sarcopenia research 2010 to 2012 and their relevance for cardiology</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Banach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Med Sci</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="166" to="171" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Urinary creatinine excretion, an indirect measure of muscle mass, is an independent predictor of cardiovascular disease and mortality in the general population</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Oterdoom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">T</forename><surname>Gansevoort</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Schouten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>De Jong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Gans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Bakker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Atherosclerosis</title>
		<imprint>
			<biblScope unit="volume">207</biblScope>
			<biblScope unit="page" from="534" to="540" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">The potential role of plasma gelsolin in dialysis-related protein-energy wasting</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Thadhani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood Purif</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="99" to="101" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Plasma gelsolin and circulating actin correlate with hemodialysis mortality</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sampath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Karumanchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tamez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bhan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Isakova</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Soc Nephrol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="1140" to="1148" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Association of the malnutrition-inflammation score with clinical outcomes in kidney transplant recipients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Z</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Czira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rudas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ujszaszi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lindner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fornadi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Kidney Dis</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="101" to="108" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials</title>
		<author>
			<persName><forename type="first">E</forename><surname>Marzetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Calvani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cesari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">W</forename><surname>Buford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lorenzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">J</forename><surname>Behnke</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Biochem Cell Biol</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="2288" to="2301" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">The wasting continuum in heart failure: from sarcopenia to cachexia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc Nutr Soc</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="1" to="11" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Maggioni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Dahlström</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Filippatos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zannad</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="1173" to="1184" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Negassa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajs</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Afzal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Poole-Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">N</forename><surname>Cohn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<biblScope unit="page" from="1077" to="1083" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Rosiglitazone and imidapril alone or in combination alleviate muscle and adipose depletion in a murine cancer cachexia model</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Z</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Xiao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="323" to="332" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">Evidence for an effect of ACE inhibitors on cancer cachexia</title>
		<author>
			<persName><forename type="first">N</forename><surname>Schanze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">139</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Aerobic exercise training as therapy for cardiac and cancer cachexia</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Alves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Da Cunha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Da Paixão</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Brum</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Life Sci</title>
		<imprint>
			<biblScope unit="volume">125</biblScope>
			<biblScope unit="page" from="9" to="14" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Resistance exercise: an effective strategy to reverse muscle wasting in hemodialysis patients?</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Rhee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantar-Zadeh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="177" to="180" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Anabolic exercise in haemodialysis patients: a randomised controlled pilot study</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Kirkman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mullins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Junglee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kumwenda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Jibani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Macdonald</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="199" to="207" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Daily physical activity and physical function in adult maintenance hemodialysis patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Shapiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Porszasz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bross</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="209" to="220" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Exercise for cancer cachexia in adults : executive summary of a Cochrane Collaboration systematic review</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Grande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Silva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Maddocks</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="208" to="211" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Exercise training in heart failure: from theory to practice. A consensus document of the heart failure association and the european association for cardiovascular prevention and rehabilitation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Piepoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Conraads</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Corrà</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dickstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Francis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Jaarsma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="347" to="357" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">statement: key concepts and advances in pulmonary rehabilitation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Spruit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Singh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garvey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zuwallack</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Nici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rochester</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Respir Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">188</biblScope>
			<biblScope unit="page" from="e13" to="64" />
			<date type="published" when="2013">2013</date>
			<publisher>European Respiratory Society</publisher>
		</imprint>
	</monogr>
	<note>ATS/ERS Task Force on PulmonaryRehabilitation. An official</note>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Are we closer to having drugs to treat muscle wasting disease?</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="83" to="87" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Mcmurray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Adamopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Auricchio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Böhm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Dickstein</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="803" to="869" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">High-versus moderate-intensity aerobic exercise training effects on skeletal muscleof infarcted rats</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Bechara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Bozi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Jannig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">W</forename><surname>Monteiro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">M</forename><surname>Dourado</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Appl Physiol</title>
		<imprint>
			<biblScope unit="volume">114</biblScope>
			<biblScope unit="page" from="1029" to="1041" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Protein supplementation improves physical performance in frail elderly people: a randomized, double-blind, placebo-controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tieland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Van De Rest</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Dirks</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Van Der Zwaluw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mensink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">J</forename><surname>Van Loon</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Med Dir Assoc</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="720" to="726" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group</title>
		<author>
			<persName><forename type="first">J</forename><surname>Bauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Biolo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cederholm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cesari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Cruz-Jentoft</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Med Dir Assoc</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="542" to="559" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">The effects of a high-caloric protein rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study</title>
		<author>
			<persName><forename type="first">P</forename><surname>Rozentryt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">U</forename><surname>Nowak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantarzadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Polonski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="35" to="42" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study</title>
		<author>
			<persName><forename type="first">S</forename><surname>Fumagalli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fattirolli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Guarducci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Cellai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Baldasseroni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tarantini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cardiol</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="211" to="217" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action</title>
		<author>
			<persName><forename type="first">V</forename><surname>Dutt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Dabur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Injeti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mittal</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Res</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="86" to="100" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management</title>
		<author>
			<persName><forename type="first">H</forename><surname>Wakabayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sakuma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="269" to="277" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Changes in body composition in heart failure patients after a resistance exercise program and branched chain amino acid supplementation</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Pineda-Juarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Sanchez-Ortiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Castillo-Martínez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Orea-Tejeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Cervantes-Gaytan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Keirns-Davis</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.clnu.2015.02.004</idno>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Epub ahead of print</note>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Anti-TNF treatment reduces rat skeletal muscle wasting in monocrotaline-induced cardiac cachexia</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Steffen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Lees</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">W</forename><surname>Booth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Appl Physiol</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="1950" to="1958" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Thalidomide and cancer cachexia: old problem, new hope?</title>
		<author>
			<persName><forename type="first">M</forename><surname>Stroud</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Gut</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="447" to="448" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">A Phase II dose titration study of thalidomide for cancerassociated anorexia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lasheen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Walsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Mahmoud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Bicanovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lagman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pain Symptom Manage</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="78" to="86" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Xanthine derivatives: comparison between suppression of tumour necrosis factoralpha production and inhibition of cAMP phosphodiesterase activity</title>
		<author>
			<persName><forename type="first">J</forename><surname>Semmler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Gebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Eisenhut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Schönharting</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Alléra</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunology</title>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="page" from="520" to="525" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">HWA 448) inhibits enhanced skeletal muscle ubiquitinproteasome-dependent proteolysis in cancer and septic rats</title>
		<author>
			<persName><forename type="first">L</forename><surname>Combaret</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tilignac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Claustre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Voisin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Taillandier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Obled</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem J</title>
		<imprint>
			<biblScope unit="volume">361</biblScope>
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Phase II study of the novel peptidenucleic acid OHR118 in the management of cancer-related anorexia/cachexia</title>
		<author>
			<persName><forename type="first">M</forename><surname>Chasen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Z</forename><surname>Hirschman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bhargava</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Med Dir Assoc</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="62" to="67" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Clinical studies on the treatment of cancer cachexia with megestrol acetate plus thalidomide</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Z</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Shi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chemotherapy</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="461" to="467" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Greig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Johns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Macdonald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">A</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Skipworth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Support Care Cancer</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="1269" to="1275" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">A randomized, double-blind, placebo controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Cuvelier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">J</forename><surname>Baker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Peddie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Casey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Lambert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Distefano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Blood Cancer</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="672" to="679" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">A new look at an old drug for the treatment of cancer cachexia: megestrol acetate</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argilés</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Anguera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Stemmler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Nutr</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="319" to="324" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Mccarthy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Crowder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dryden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Williams</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Pharmacol</title>
		<imprint>
			<biblScope unit="volume">265</biblScope>
			<biblScope unit="page" from="99" to="102" />
			<date type="published" when="1994">1994</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">Managing cancer-related anorexia/cachexia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Mantovani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Macciò</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Massa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Madeddu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Drugs</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="499" to="514" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Residual Ca2+ channel current modulation by megestrol acetate via a g-protein alpha s-subunit in rat hypothalamic neurones</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Spence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Plata-Salamán</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ffrench-Mullen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Physiol</title>
		<imprint>
			<biblScope unit="volume">487</biblScope>
			<biblScope unit="page" from="291" to="303" />
			<date type="published" when="1995">1995</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Δ9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Srivastava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bis</forename><surname>Srivastava</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Brouhard</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunopharmacology</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="179" to="185" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Marijuana components stimulate human peripheral blood mononuclear cell secretion of interferon-gamma and suppress interleukin-1 alpha in vitro</title>
		<author>
			<persName><forename type="first">B</forename><surname>Watzl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Scuderi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Watson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Immunopharmacol</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1091" to="1097" />
			<date type="published" when="1991">1991</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model</title>
		<author>
			<persName><forename type="first">K</forename><surname>Lenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Schur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Datta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Culler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="63" to="69" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">Effects of ghrelin administration on left ventricular function, exercise capacity, and muscle wasting in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">N</forename><surname>Nagaya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moriya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yasumura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Uematsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Ono</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Shimizu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">110</biblScope>
			<biblScope unit="page" from="3674" to="3679" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">Efficacy and safety results from a phase II study of anamorelin HCl, a ghrelin receptor agonist, in NSCLC patients</title>
		<author>
			<persName><forename type="first">J</forename><surname>Temel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bondarde</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Duus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Allen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="295" to="343" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Abstract 5-01</note>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Anamorelin HCl for the treatment of anorexia-cachexia in lung cancer: study design and baseline characteristics of patients in the phase III clinical trial ROMANA 2 (HT-ANAM-302)</title>
		<author>
			<persName><forename type="first">A</forename><surname>Abernethy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Temel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Currow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gleich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Friend</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="295" to="343" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>Abstract 5-02</note>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Effects of an oral growth hormone secretagogue in older adults</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">D</forename><surname>Petrie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Landschulz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Maclean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lyles</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="1198" to="1206" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">Recent developments in the treatment of cachexia: highlights from the 6th Cachexia Conference</title>
		<author>
			<persName><forename type="first">N</forename><surname>Ebner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">G</forename><surname>Werner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="45" to="50" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo controlled phase II trial</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Dalton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">G</forename><surname>Barnette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Bohl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hancock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Dodson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="153" to="161" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="253" to="259" />
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">A selective androgen receptor modulator (SARM), increases lean body mass (LBM) in advanced non-small cell lung cancer patients in two pivotal, international phase 3 trials</title>
		<author>
			<persName><forename type="first">J</forename><surname>Crawford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Dalton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hancock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Johnston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Steiner</surname></persName>
		</author>
		<author>
			<persName><surname>Enobosarm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="35" to="78" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Abstract 5-15</note>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Dobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Boccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Croot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Gabrail</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Dalton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Hancock</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="335" to="345" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Anabolic effect of a novel long-acting SARM in rat ORX model</title>
		<author>
			<persName><forename type="first">K</forename><surname>Takagi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Horie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fujita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tanokura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hosoda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Watanabe</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="295" to="343" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">Characterization of GLPG0492, a selective androgen receptor modulator, in a mouse model of hind limb immobilization</title>
		<author>
			<persName><forename type="first">R</forename><surname>Blanqué</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lepescheux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Auberval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Minet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Merciris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cottereaux</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Musculoskelet Disord</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">291</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cozzoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">F</forename><surname>Capogrosso</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">T</forename><surname>Sblendorio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Dinardo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Jagerschmidt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Namour</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Res</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="9" to="24" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">The potential and the pitfalls of beta-adrenoceptor agonists for the management of skeletal muscle wasting</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Ryall</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Lynch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pharmacol Ther</title>
		<imprint>
			<biblScope unit="volume">120</biblScope>
			<biblScope unit="page" from="219" to="232" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">Serum metabolic profiles reveal the effect of formoterol on cachexia in tumor-bearing mice</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Quanjun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Genjin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Lili</forename><forename type="middle">W</forename><surname>Bin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">L</forename><surname>Qi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Biosyst</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="3015" to="3025" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">The anabolic catabolic transforming agent (ACTA) espindolol increases muscle mass and decreases fat mass in old rats</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Pötsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Beadle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="149" to="158" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">The ACT-ONE trial, a multicentre, randomised, double-blind, placebocontrolled, dose-finding study of the anabolic/catabolic transforming agent, MT-102 in subjects with cachexia related to stage III and IV non-small cell lung cancer and colorectal cancer: study design</title>
		<author>
			<persName><forename type="first">Stewart</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Srinivasan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Surendran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chiramana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Vangipuram</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Bhatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">N</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="201" to="207" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">Espindolol for the treatment and prevention of cachexia in patients with stage III/IV non-small cell lung cancer or colorectal cancer (ACT-ONE): randomised, double-blind, placebo-controlled, international multi-centre phase II study</title>
		<author>
			<persName><forename type="first">Stewart</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Fuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Prabhash</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Von Haeling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brown</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="35" to="78" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
	<note>Abstract 5-19</note>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Formoterol in the treatment of experimental cancer cachexia: effects on heart function</title>
		<author>
			<persName><forename type="first">M</forename><surname>Toledo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Busquets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>López-Soriano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="315" to="320" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">Efficacy of REGN1033, a fully human antimyostatin antagonist antibody, in rodent muscle function</title>
		<author>
			<persName><forename type="first">R</forename><surname>Bauerlein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pangilinan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Salzler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Abrahams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gromada</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="295" to="343" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main">Reversal of cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival</title>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Jiao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="531" to="543" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Growth factor delivery methods in the management of sports injuries: the state of play</title>
		<author>
			<persName><forename type="first">L</forename><surname>Creaney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hamilton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Sports Med</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="314" to="320" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main">Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel</title>
		<author>
			<persName><forename type="first">M</forename><surname>Banach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rizzo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>Toth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Farnier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Davidson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Al-Rasadi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Arch Med Sci</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1" to="23" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">Simvastatin reduces wasting and improves cardiac function as well as outcome in experimental cancer cachexia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Paulus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Flach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="3412" to="3418" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main">Statins and dietary and serum cholesterol are associated with increased lean mass following resistance training</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Reichman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Andrews</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Maclean</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sheather</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Gerontol A Biol Sci Med Sci</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1164" to="1171" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main">Stem cells for skeletal muscle regeneration: therapeutic potential and roadblocks</title>
		<author>
			<persName><forename type="first">F</forename><surname>Rinaldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Perlingeiro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transl Res</title>
		<imprint>
			<biblScope unit="volume">163</biblScope>
			<biblScope unit="page" from="409" to="417" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main">Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure</title>
		<author>
			<persName><forename type="first">T</forename><surname>Khawaja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chokshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zizola</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="297" to="305" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main">Why cachexia kills: examining the causality of poor outcomes in wasting conditions</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantar-Zadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rhee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Sim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Stenvinkel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Kovesdy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="89" to="94" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main">Biomarkers for physical frailty and sarcopenia: state of the science and future developments</title>
		<author>
			<persName><forename type="first">R</forename><surname>Calvani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Marini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cesari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tosato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
		<idno type="DOI">10.1002/jcsm.12051</idno>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="1" to="17" />
			<date type="published" when="2013">2015. 2013</date>
		</imprint>
	</monogr>
	<note>Serological muscle loss biomarkers: an overview of current concepts and future possibilities</note>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main">Consensus statement from the 2014 International Microdialysis Forum</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Hutchinson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Jalloh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Helmy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Carpenter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Rostami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Bellander</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Intensive Care Med</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="1517" to="1528" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main">Pharmacokinetics of drugs in cachectic patients: a systematic review</title>
		<author>
			<persName><forename type="first">K</forename><surname>Trobec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kerec</forename><surname>Kos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Lainscak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">e79603</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main">Influence of cancer cachexia on drug liver metabolism and renal elimination in rats</title>
		<author>
			<persName><forename type="first">Cvan</forename><surname>Trobec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Kerec</forename><surname>Kos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trontelj</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Grabnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Palus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="45" to="52" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main">Request for regulatory guidance for cancer cachexia intervention trials</title>
		<author>
			<persName><forename type="first">Kch</forename><surname>Fearon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Argiles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">E</forename><surname>Baracos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bernabei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajs</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Crawford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="272" to="274" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main">Inflammation based regulation of cancer cachexia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Onesti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Guttridge</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Res Int</title>
		<imprint>
			<biblScope unit="page">168407</biblScope>
			<date type="published" when="2014">2014. 2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main">Crossroads of cytokine signaling-the chase to stop muscle cachexia</title>
		<author>
			<persName><forename type="first">B</forename><surname>Pajak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Orzechowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Pijet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Pijet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pogorzelska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gajkowska</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Physiol Pharmacol</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="251" to="264" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main">Implications of cross-talk between tumour necrosis factor and insulin-like growth factor-1 signalling in skeletal muscle</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Grounds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Radley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Gebski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Bogoyevitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shavlakadze</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Exp Pharmacol Physiol</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="846" to="851" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b173">
	<analytic>
		<title level="a" type="main">Tumor necrosis factor as a pharmacological target</title>
		<author>
			<persName><forename type="first">P</forename><surname>Ghezzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cerami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Methods Mol Med</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page" from="1" to="8" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b174">
	<analytic>
		<title level="a" type="main">Cachectin/ TNF or IL-1 alpha induces cachexia with redistribution of body proteins</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Fong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">L</forename><surname>Moldawer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Marano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Barber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Manogue</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol</title>
		<imprint>
			<biblScope unit="volume">256</biblScope>
			<biblScope unit="page" from="R659" to="R665" />
			<date type="published" when="1989">1989</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b175">
	<analytic>
		<title level="a" type="main">IL-6 regulation on skeletal muscle mitochondrial remodeling during cancer cachexia in the ApcMin/+ mouse</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Puppa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Price</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Baynes</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Skelet Muscle</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page">14</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b176">
	<analytic>
		<title level="a" type="main">Muscle mTORC1 suppression by IL-6 during cancer cachexia: a role for AMPK</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Puppa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sato</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Welle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Carson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">304</biblScope>
			<biblScope unit="page" from="E1042" to="E1052" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b177">
	<analytic>
		<title level="a" type="main">The diverse roles of adiponectin in non-small-cell lung cancer: current data and future perspectives</title>
		<author>
			<persName><forename type="first">P</forename><surname>Boura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Loukides</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Grapsa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Achimastos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Syrigos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Future Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="2193" to="2203" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b178">
	<analytic>
		<title level="a" type="main">Hormones of adipose tissue and their biologic role in lung cancer</title>
		<author>
			<persName><forename type="first">E</forename><surname>Ntikoudi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kiagia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Boura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Syrigos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Treat Rev</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="22" to="30" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b179">
	<analytic>
		<title level="a" type="main">Exploiting the therapeutic potential of leptin signaling in cachexia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">H</forename><surname>Mak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gertler</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Support Palliat Care</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="352" to="357" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b180">
	<analytic>
		<title level="a" type="main">Growth hormone, insulin-like growth factor 1, and insulin signaling-a pharmacological target in body wasting and cachexia</title>
		<author>
			<persName><forename type="first">K</forename><surname>Trobec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lainscak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="191" to="200" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b181">
	<analytic>
		<title level="a" type="main">Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure</title>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rauchhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Ponikowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">F</forename><surname>Godsland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">O</forename><surname>Okonko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Am Coll Cardiol</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1019" to="1026" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b182">
	<analytic>
		<title level="a" type="main">Cancer metabolism: a waste of insulin interference</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Petruzzelli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">521</biblScope>
			<biblScope unit="page" from="430" to="431" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b183">
	<analytic>
		<title level="a" type="main">The role of insulin resistance in the development of muscle wasting during cancer cachexia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Honors</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Kinzig</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="5" to="11" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b184">
	<analytic>
		<title level="a" type="main">The assessment and management of cancer cachexia: hypogonadism and hypermetabolism among supportive and palliative care patients</title>
		<author>
			<persName><forename type="first">R</forename><surname>Dev</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Support Palliat Care</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="279" to="285" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b185">
	<analytic>
		<title level="a" type="main">Growth hormone: growth hormone resistance in chronic heart failure and its therapeutic implications</title>
		<author>
			<persName><forename type="first">M</forename><surname>Cicoira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Kalra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Card Fail</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="219" to="226" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b186">
	<analytic>
		<title level="a" type="main">The growth hormone and insulin-like growth factor 1 axis in heart failure</title>
		<author>
			<persName><forename type="first">P</forename><surname>Delafontaine</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Brink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Endocrinol (Paris)</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="22" to="26" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b187">
	<analytic>
		<title level="a" type="main">Growth hormone and experimental cancer cachexia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Svaninger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Isaksson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lundholm</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="1359" to="1365" />
			<date type="published" when="1987">1987</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b188">
	<analytic>
		<title level="a" type="main">Insight into the growth hormoneinsulin-like growth factor-I axis in cancer cachexia</title>
		<author>
			<persName><forename type="first">C</forename><surname>Bing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Nutr</title>
		<imprint>
			<biblScope unit="volume">93</biblScope>
			<biblScope unit="page" from="761" to="763" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b189">
	<analytic>
		<title level="a" type="main">Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Fogelman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mohammed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Katz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Prado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lieffers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="307" to="313" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b190">
	<analytic>
		<title level="a" type="main">Uric acid in cachectic and noncachectic patients with chronic heart failure: relationship to leg vascular resistance</title>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rauchhaus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">G</forename><surname>Florea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Bolger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Davos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am Heart J</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="792" to="799" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b191">
	<analytic>
		<title level="a" type="main">The xanthine oxidase inhibitor oxypurinol reduces cancer cachexia-induced cardiomyopathy</title>
		<author>
			<persName><forename type="first">J</forename><surname>Springer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tschirner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hartman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Doehner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Cardiol</title>
		<imprint>
			<biblScope unit="volume">168</biblScope>
			<biblScope unit="page" from="3527" to="3531" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b192">
	<analytic>
		<title level="a" type="main">Mechanism of increased lipolysis in cancer cachexia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Agustsson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Rydén</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Hoffstedt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Van Harmelen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Dicker</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Laurencikiene</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="5531" to="5537" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b193">
	<analytic>
		<title level="a" type="main">Control of lipolysis by natriuretic peptides and cyclic GMP</title>
		<author>
			<persName><forename type="first">M</forename><surname>Lafontan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Moro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Berlan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Crampes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sengenes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Galitzky</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Trends Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="130" to="137" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b194">
	<analytic>
		<title level="a" type="main">Exercise intolerance in chronic heart failure: the role of cortisol and the catabolic state</title>
		<author>
			<persName><forename type="first">G</forename><surname>Tzanis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dimopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Agapitou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Nanas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Heart Fail Rep</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="70" to="79" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b195">
	<analytic>
		<title level="a" type="main">Association between serum cortisol and testosterone levels, opioid therapy, and symptom distress in patients with advanced cancer</title>
		<author>
			<persName><forename type="first">R</forename><surname>Dev</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Hui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Dalal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">I</forename><surname>Nooruddin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yennurajalingam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Del</forename><surname>Fabbro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pain Symptom Manage</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="788" to="795" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b196">
	<analytic>
		<title level="a" type="main">Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">D</forename><surname>Müller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Perez-Tilve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">T</forename><surname>Pfluger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Tschöp</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page" from="159" to="167" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b197">
	<analytic>
		<title level="a" type="main">Ghrelin: from discovery to cancer cachexia therapy</title>
		<author>
			<persName><forename type="first">A</forename><surname>Molfino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Formiconi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Rossi Fanelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Muscaritoli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Clin Nutr Metab Care</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="471" to="476" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b198">
	<analytic>
		<title level="a" type="main">Cardiac myostatin upregulation occurs immediately after myocardial ischemia and is involved in skeletal muscle activation of atrophy</title>
		<author>
			<persName><forename type="first">E</forename><surname>Castillero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Akashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Najjar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ji</forename><forename type="middle">R</forename><surname>Kennel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem Biophys Res Commun</title>
		<imprint>
			<biblScope unit="volume">457</biblScope>
			<biblScope unit="page" from="106" to="111" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b199">
	<analytic>
		<title level="a" type="main">Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure</title>
		<author>
			<persName><forename type="first">J</forename><surname>Heineke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Auger-Messier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sargent</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>York</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Welle</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Circulation</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="page" from="419" to="425" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b200">
	<analytic>
		<title level="a" type="main">Myostatin activation in patients with advanced heart failure and after mechanical unloading</title>
		<author>
			<persName><forename type="first">I</forename><surname>George</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Bish</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Kamalakkannan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Petrilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Oz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Naka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="444" to="453" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b201">
	<analytic>
		<title level="a" type="main">Increased plasma myostatin in heart failure</title>
		<author>
			<persName><forename type="first">D</forename><surname>Gruson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Ketelslegers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Rousseau</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Heart Fail</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="734" to="736" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b202">
	<analytic>
		<title level="a" type="main">Exercise training leads to a reduction of elevated myostatin levels in patients with chronic heart failure</title>
		<author>
			<persName><forename type="first">K</forename><surname>Lenk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Erbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Hollriege</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Beck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Linke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gielen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Prev Cardiol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="404" to="411" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b203">
	<analytic>
		<title level="a" type="main">Serum myostatin levels in chronic heart failure</title>
		<author>
			<persName><forename type="first">E</forename><surname>Zamora</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Simo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lupon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Galán</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Urrutia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>González</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Rev Esp Cardiol</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="992" to="996" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b204">
	<analytic>
		<title level="a" type="main">Role of Activin A and myostatin in human cancer cachexia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Loumaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Barsy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nachit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Frateur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Van Maanen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">100</biblScope>
			<biblScope unit="page" from="2030" to="2038" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b205">
	<analytic>
		<title level="a" type="main">Myostatin is a novel tumoral factor that induces cancer cachexia</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lokireddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">W</forename><surname>Wijesoma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bonala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Sze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mcfarlane</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biochem J</title>
		<imprint>
			<biblScope unit="volume">446</biblScope>
			<biblScope unit="page" from="23" to="36" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b206">
	<analytic>
		<title level="a" type="main">Formoterol treatment down regulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats</title>
		<author>
			<persName><forename type="first">S</forename><surname>Busquets</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toledo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Marmonti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Orpí</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Capdevila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Betancourt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Oncol Lett</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="185" to="189" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b207">
	<analytic>
		<title level="a" type="main">Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mallidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bhasin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mahabadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Artaza</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gonzalez-Cadavid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Physiol Endocrinol Metab</title>
		<imprint>
			<biblScope unit="volume">285</biblScope>
			<biblScope unit="page" from="E363" to="E371" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b208">
	<analytic>
		<title level="a" type="main">Myostatin upregulation is associated with the skeletal muscle response to hypoxic stimuli</title>
		<author>
			<persName><forename type="first">M</forename><surname>Hayot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Vernus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Carnac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jean</forename><forename type="middle">E</forename><surname>Allen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Endocrinol</title>
		<imprint>
			<biblScope unit="volume">332</biblScope>
			<biblScope unit="page" from="38" to="47" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b209">
	<analytic>
		<title level="a" type="main">Mortality prediction by surrogates of body composition: an examination of the obesity paradox in hemodialysis patients using composite ranking score analysis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kalantar-Zadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Streja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Z</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">R</forename><surname>Lukowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Krishnan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Kovesdy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Epidemiol</title>
		<imprint>
			<biblScope unit="volume">175</biblScope>
			<biblScope unit="page" from="793" to="803" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b210">
	<analytic>
		<title level="a" type="main">Associations of body mass index and weight loss with mortality in transplant-waitlisted maintenance hemodialysis patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Z</forename><surname>Molnar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Streja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Kovesdy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bunnapradist</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Sampaio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Jing</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Transplant</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="725" to="736" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b211">
	<analytic>
		<title level="a" type="main">Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update</title>
		<author>
			<persName><forename type="first">S</forename><surname>Von Haehling</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Morley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ajs</forename><surname>Coats</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Anker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Cachexia Sarcopenia Muscle</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="315" to="316" />
			<date type="published" when="2015">2015. 2015</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
